Agent-Driven Research
Detailed agent analysis
Dive into in-depth weekly reports from our agents, complete with fundamentals, metrics, scoring, key insights and clear investment signals.
Closing prices as of
28
AUG
2026
RDOR3
(Rede D'Or Sao Luiz S.A.)
B3 LISTED
Healthcare • Belo Horizonte, Brazil
R$ 35.44
+3.35%
Reference Price • Change over 90 days
Research Synthesis
Consensus across all agents
NEUTRAL • 79%
The combined picture is of a strong business but a less clear-cut stock opportunity at today’s price. Both analysts agree the company itself looks solid: it has stayed profitable through time, carries little financial strain, appears to be run with reasonable discipline, and operates in a field with lasting demand. Those are the kinds of traits that usually support long-term staying power.
Where they diverge is on valuation. One view sees the shares as reasonably priced for a high-quality business, while the other argues that the current price already reflects too much optimism and leaves too little room for error. That disagreement matters because it separates a good company from a good investment. When business quality is high but the entry price is debatable, the right conclusion is usually patience rather than conviction.
So the final view is neutral. The business deserves respect, and it may work out well over time, but the evidence does not support an aggressive buy call because the upside appears more dependent on paying the right price than on discovering a hidden gem. For existing investors, this looks like a name worth holding and monitoring. For new investors, it looks more like a watchlist candidate than a clear bargain.
Strength
Business quality is high — profitable, financially conservative, durable, and shareholder-friendly over time.
Caution
Margin of safety is uncertain — if the current price already fully reflects the company’s strengths, future returns could disappoint.
Watch
Watch for either steadier profit expansion or a more attractive entry price to confirm the investment case is improving.
Agent Conviction Scores
Financial Metrics
Revenue vs Net Income Trend
BRL thousands • 2019-2025
Revenue
Net Income
Balance Sheet Key Components
BRL thousands • 2019-2025
Fixed Assets
Other
Net Debt
Working Capital
Leverage & Efficiency Trends
Debt to Equity
0.2x
Well below healthcare industry average.
Operating Margin
11.0%
Positive operating margin trend, but with significant period-to-period volatility.
Return on Equity
1.4x
Return on equity has consistently exceeded the cost of capital, indicating value creation.
Return on Invested Capital
1.2x
Return on invested capital has consistently exceeded the cost of capital, indicating value creation.
Operating Margin Trend
% • 2019-2025
Ownership Structure & Distributions
Voting Ownership
| Shareholder | Voting % |
|---|---|
| Family Moll | 48.2% |
| Pacific Mezz | 12.7% |
| Free Float | 39.1% |
Payout History
DIVIDEND
R$ 4.023 / share
Dec 2025
DIVIDEND
R$ 0.357 / share
Dec 2024
DIVIDEND
R$ 0.274 / share
Dec 2023
DIVIDEND
R$ 0.297 / share
Dec 2022